Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer: Adjuvant Systemic Therapy

November 11, 2014

Join Kristine Kokeny, MD and John Ward, MD as they present their multidisciplinary expertise on a range of cases pertaining to adjuvant systemic therapy for breast cancer.

The purpose of adjuvant systemic therapy is to improve the disease-free survival and overall survival rates after treatment with local therapies (surgery with or without radiation). The incorporation of adjuvant therapy has made a significant positive impact on clinical outcomes in patients with breast cancer.

The benefit from adjuvant systemic therapy differs according to breast cancer subtype. Algorithms have been published estimating rates of recurrence, and a validated computer‑based model (Adjuvant! Online) is available to estimate 10‑year disease‑free and overall survival. These tools aid the clinicians in objectively estimating outcome with local treatment only and in estimating the absolute benefits expected from systemic adjuvant therapy.

Gene‑based assays are used increasingly in making decisions regarding the use of adjuvant chemotherapy in hormone receptor positive, lymph node negative tumors. These assays help quantify risk and make individualized decisions regarding the benefit of adjuvant chemotherapy based on risk of recurrence for early stage breast cancer. The threshold for using adjuvant chemotherapy remains a controversial issue. While the benefit of adjuvant chemotherapy to patients with high risk of recurrence is clear, the additional benefit from adjuvant chemotherapy in addition to endocrine therapy for patients with intermediate‑risk (as assessed by the gene‑based assays) is currently unclear. Prospective randomized clinical trials are addressing the use of Oncotype DX and MammaPrint as predictive and/or prognostic tools in women with early‑stage, lymph node‑negative breast cancer.

Tumor biomarkers (ER/PR and HER-2 receptors) are most useful for predicting response to particular therapies (i.e., endocrine therapy and/or HER2 targeted therapy). Adequate standardization and validation of these biomarker assays used is a concern, and false‑positive determinations are common. The NCCN Panel endorses the recently updated ASCO/CAP recommendations for HER2 testing for quality control and interpretation of results.

Endocrine therapy is mainstay adjuvant treatment for all patients with hormone receptor positive breast cancer regardless of age, lymph node status, and treatment with adjuvant chemotherapy. An ongoing issue in the treatment of hormone receptor positive disease is duration of endocrine therapy.  Selecting the most efficient treatment strategy based on patient characteristics and adverse effects can be challenging. For postmenopausal women the treatment algorithm is complex with several different adjuvant strategies such as: treatment with aromatase inhibitors (AI); versus the sequential strategy, starting with tamoxifen and switching to AI; versus treatment with tamoxifen alone 10 years. The results of a recent large randomized trial (ATLAS) show that for premenopausal women with early hormone positive  breast cancer, 10 years of tamoxifen is better than stopping after 5 years. The NCCN guidelines recommendations for adjuvant endocrine therapy incorporate the findings of the ATLAS trial.

Target Audience

This educational activity is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Apply NCCN Guideline-based therapeutic strategies in the treatment of patients
  • Describe the multidisciplinary aspects of patient management for adjuvant systemic therapy for breast cancer
  • Identify the key characteristics that trigger decision points
  • Recognize situations where optimal care may require adapting the Guideline recommendations to individual circumstances
Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Exelixis Inc.
  • Genentech BioOncology
  • Janssen Biotech, Inc.
  • Novartis Oncology
  • Takeda Oncology

Supported by a grant from Onyx Pharmaceuticals.

Supported by independent educational grants from Merck and Prometheus Laboratories Inc.

Supported by an unrestricted, educational grant from Celgene Corporation.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
11/09/2014
Course expires: 
01/09/2015
Event starts: 
11/11/2014 - 11:00am
Event ends: 
11/11/2014 - 12:00pm
Cost:
$0.00

Kristine Kokeny, MD
Huntsman Cancer Institute at the University of Utah

John Ward, MD
Huntsman Cancer Institute at the University of Utah

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
11/09/2014
Course expires: 
01/09/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing